Characteristics and Factors Associated With Coronavirus Disease 2019 Infection, Hospitalization, and Mortality Across Race and Ethnicity.


Journal

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213

Informations de publication

Date de publication:
16 12 2021
Historique:
received: 27 10 2020
pubmed: 21 2 2021
medline: 24 12 2021
entrez: 20 2 2021
Statut: ppublish

Résumé

Data on the characteristics of coronavirus disease 2019 (COVID-19) patients disaggregated by race/ethnicity remains limited. We evaluated the sociodemographic and clinical characteristics of patients across racial/ethnic groups and assessed their associations with COVID-19 outcomes. This retrospective cohort study examined 629 953 patients tested for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a large health system spanning California, Oregon, and Washington between March 1 and December 31, 2020. Sociodemographic and clinical characteristics were obtained from electronic health records. Odds of SARS-CoV-2 infection, COVID-19 hospitalization, and in-hospital death were assessed with multivariate logistic regression. A total of 570 298 patients with known race/ethnicity were tested for SARS-CoV-2, of whom 27.8% were non-White minorities: 54 645 individuals tested positive, with minorities representing 50.1%. Hispanics represented 34.3% of infections but only 13.4% of tests. Although generally younger than White patients, Hispanics had higher rates of diabetes but fewer other comorbidities. A total of 8536 patients were hospitalized and 1246 died, of whom 56.1% and 54.4% were non-White, respectively. Racial/ethnic distributions of outcomes across the health system tracked with state-level statistics. Increased odds of testing positive and hospitalization were associated with all minority races/ethnicities. Hispanic patients also exhibited increased morbidity, and Hispanic race/ethnicity was associated with in-hospital mortality (odds ratio [OR], 1.39; 95% confidence interval [CI], 1.14-1.70). Major healthcare disparities were evident, especially among Hispanics who tested positive at a higher rate, required excess hospitalization and mechanical ventilation, and had higher odds of in-hospital mortality despite younger age. Targeted, culturally responsive interventions and equitable vaccine development and distribution are needed to address the increased risk of poorer COVID-19 outcomes among minority populations.

Sections du résumé

BACKGROUND
Data on the characteristics of coronavirus disease 2019 (COVID-19) patients disaggregated by race/ethnicity remains limited. We evaluated the sociodemographic and clinical characteristics of patients across racial/ethnic groups and assessed their associations with COVID-19 outcomes.
METHODS
This retrospective cohort study examined 629 953 patients tested for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a large health system spanning California, Oregon, and Washington between March 1 and December 31, 2020. Sociodemographic and clinical characteristics were obtained from electronic health records. Odds of SARS-CoV-2 infection, COVID-19 hospitalization, and in-hospital death were assessed with multivariate logistic regression.
RESULTS
A total of 570 298 patients with known race/ethnicity were tested for SARS-CoV-2, of whom 27.8% were non-White minorities: 54 645 individuals tested positive, with minorities representing 50.1%. Hispanics represented 34.3% of infections but only 13.4% of tests. Although generally younger than White patients, Hispanics had higher rates of diabetes but fewer other comorbidities. A total of 8536 patients were hospitalized and 1246 died, of whom 56.1% and 54.4% were non-White, respectively. Racial/ethnic distributions of outcomes across the health system tracked with state-level statistics. Increased odds of testing positive and hospitalization were associated with all minority races/ethnicities. Hispanic patients also exhibited increased morbidity, and Hispanic race/ethnicity was associated with in-hospital mortality (odds ratio [OR], 1.39; 95% confidence interval [CI], 1.14-1.70).
CONCLUSION
Major healthcare disparities were evident, especially among Hispanics who tested positive at a higher rate, required excess hospitalization and mechanical ventilation, and had higher odds of in-hospital mortality despite younger age. Targeted, culturally responsive interventions and equitable vaccine development and distribution are needed to address the increased risk of poorer COVID-19 outcomes among minority populations.

Identifiants

pubmed: 33608710
pii: 6145124
doi: 10.1093/cid/ciab154
pmc: PMC7929051
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2193-2204

Subventions

Organisme : NCATS NIH HHS
ID : OT2 TR003443
Pays : United States
Organisme : Biomedical Advanced Research and Development Authority
ID : HHSO10201600031C
Organisme : NIH HHS
ID : OT2 TR003443
Pays : United States

Commentaires et corrections

Type : UpdateOf

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Références

JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
MMWR Morb Mortal Wkly Rep. 2020 Aug 21;69(33):1122-1126
pubmed: 32817602
JAMA Netw Open. 2020 Aug 03;3(8):e2018039
pubmed: 32809033
JAMA. 2020 Jul 28;324(4):390-392
pubmed: 32556085
Med Care. 2005 Nov;43(11):1130-9
pubmed: 16224307
Contemp Clin Trials Commun. 2020 Jul 30;19:100630
pubmed: 32789282
Eur Respir J. 2020 May 14;55(5):
pubmed: 32217650
JAMA. 2020 Jun 23;323(24):2466-2467
pubmed: 32391864
BMJ Glob Health. 2020 Jun;5(6):
pubmed: 32513864
N Engl J Med. 2020 Jun 25;382(26):2534-2543
pubmed: 32459916
Clin Infect Dis. 2021 May 4;72(9):e206-e214
pubmed: 32674114
PLoS One. 2019 Jun 17;14(6):e0218462
pubmed: 31206556
J Gen Intern Med. 2020 Sep;35(9):2801-2803
pubmed: 32583345
EClinicalMedicine. 2020 Aug;25:100455
pubmed: 32838233
Obes Rev. 2020 Nov;21(11):e13128
pubmed: 32845580

Auteurs

Chengzhen L Dai (CL)

Institute for Systems Biology, Seattle, Washington, USA.

Sergey A Kornilov (SA)

Institute for Systems Biology, Seattle, Washington, USA.

Ryan T Roper (RT)

Institute for Systems Biology, Seattle, Washington, USA.

Hannah Cohen-Cline (H)

Providence Center for Outcomes Research and Education, Providence Health System, Renton, Washington, USA.

Kathleen Jade (K)

Institute for Systems Biology, Seattle, Washington, USA.

Brett Smith (B)

Institute for Systems Biology, Seattle, Washington, USA.

James R Heath (JR)

Institute for Systems Biology, Seattle, Washington, USA.
Department of Bioengineering, University of Washington, Seattle, Washington, USA.

George Diaz (G)

Providence Regional Medical Center, Everett, Washington, USA.

Jason D Goldman (JD)

Swedish Center for Research and Innovation, Swedish Medical Center, Seattle, Washington, USA.
Division of Allergy & Infectious Diseases, University of Washington, Seattle, Washington, USA.

Andrew T Magis (AT)

Institute for Systems Biology, Seattle, Washington, USA.

Jennifer J Hadlock (JJ)

Institute for Systems Biology, Seattle, Washington, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH